Latest News

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma




KENILWORTH, N.J., & BRUSSELS–(BUSINESS WIRE)—- $MRK #MRK–Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

Source link

Related posts

FDA halts all sales of pelvic mesh products tied to injuries in women

Newsemia

HIV Controllers: What You Need To Know

Newsemia

Readiness for Responding to a Severe Pandemic 100 Years After 1918

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World